The VAccine cLinical study reporting gUidEline: the VALUE checklist with explanation and elaboration
eBioMedicine, 131:106439, 2026
作者单位
- 1Evidence-based Medicine Centre, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, PR China
- 2Chinese EQUATOR Centre, Hong Kong Baptist University, Hong Kong, PR China
- 3China-Portugal Belt and Road Joint Laboratory on AI and Public Health Issues, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, PR China
- 4Vincent V.C. Woo Chinese Medicine Clinical Research Institute, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, PR China
- 5Centre for Journalology, Methodological and Implementation Research (MIR) Programme, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- 6National Immunisation Programme, Chinese Centre for Disease Control and Prevention, Beijing, PR China
- 7School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
- 8The Chinese Medicine Hospital of Hong Kong, Hong Kong, PR China
摘要
Background The number of clinical vaccine studies published each year is large and increasing as vaccinology and biotechnology advance. CONSORT and STROBE provide reporting guidelines for randomised clinical trials and observational studies, but neither addresses vaccine-specific items that should be included in vaccine study reports. Thus, there is a need to develop a guideline for reporting studies of a vaccine’s characteristics such as immunogenicity, efficacy, effectiveness, reactogenicity, and safety. Methods Using the EQUATOR Network’s “Guidance for Developers of Health Research Reporting Guidelines,” we established a core working group to conduct a systematic literature review and develop an initial list of reporting elements for vaccine studies based on CONSORT and STROBE. A 42-member Delphi expert group, composed of clinical vaccine researchers, methodologists, medical journal editors, and other experts, provided comments and suggestions on the initial checklist through two rounds of Delphi surveys. Working group members refined and finalised the checklist after each round, with the approval of advisory group members. Findings Two rounds of Delphi surveys with 42 multidisciplinary global experts generated 87 qualitative comments, producing a final 22-item checklist across 15 domains, including 9 dedicated vaccine-specific reporting items. All items were refined with detailed explanations and representative clinical study examples. Interpretation VAccine cLinical trial reporting gUidEline (VALUE) aims to provide a minimum set of vaccine- specific reporting items for experimental and observational clinical studies that evaluate characteristics of vaccines. Developed with methods recommended by the EQUATOR collaborative network, VALUE complements CONSORT and STROBE statements by addressing vaccine-specific needs, aiming to serve as a valuable resource for vaccine researchers and improve reporting of clinical vaccine studies.
关键词
- Vaccine clinical study
- Report guideline
- VALUE
- EQUATOR
- Delphi method
如何引用
Yuting Duan, Yanfang Ma, Lin Shi, et al. The VAccine cLinical study reporting gUidEline: the VALUE checklist with explanation and elaboration. eBioMedicine. 2026;131:106439. doi:10.1016/j.ebiom.2026.106439
